374
Participants
Start Date
February 18, 2025
Primary Completion Date
June 18, 2026
Study Completion Date
June 18, 2026
AZD9550
IMP injected subcutaneous, once weekly. Unit dose strength as per CSP
AZD6234
IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
Placebo comparator
Placebo matching IMP dose injected subcutaneously, once weekly.
Research Site, Maroubra
Research Site, St Leonards
Research Site, St Albans
Research Site, Maroochydore
Research Site, Norwood
Research Site, Berlin
Research Site, Falkensee
Research Site, Arlington
Research Site, Hamburg
Research Site, Oldenburg
Research Site, Decatur
Research Site, Stockbridge
Research Site, Palm Harbor
Research Site, Vestavia Hills
Research Site, Dothan
Research Site, Kingsport
Research Site, Columbus
Research Site, Essen
Research Site, Cincinnati
Research Site, Valparaiso
Research Site, South Bend
Research Site, Southfield
Research Site, Münster
Research Site, Sioux City
Research Site, Fargo
Research Site, Missoula
Research Site, Champaign
Research Site, Omaha
Research Site, Tulsa
Research Site, Houston
Research Site, Brownsville
Research Site, Albuquerque
Research Site, Huntington Park
Research Site, Cerritos
Research Site, Escondido
Research Site, Lincoln
Research Site, Sacramento
Research Site, Medford
Research Site, Renton
Research Site, Waterbury
Research Site, Calgary
Research Site, Surrey
Research Site, Guelph
Research Site, Hamilton
Research Site, Hamilton
Research Site, Sarnia
Research Site, Stouffville
Research Site, Montreal
Research Site, Chūōku
Research Site, Chūōku
Research Site, Fukuoka
Research Site, Shinjuku-ku
Research Site, Suita-shi
Lead Sponsor
AstraZeneca
INDUSTRY